The mechanism by which the phenothiazine thioridazine contributes to cure problematic drug-resistant forms of pulmonary tuberculosis: Recent patents for "new use"

Leonard Amaral, Ana Martins, G. Spengler, Attila Hunyadi, J. Molnár

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

At this moment, over half million patients suffer from multi-drug resistant tuberculosis (MDR-TB) according to the data from the WHO. A large majority is terminally ill with essentially incurable pulmonary tuberculosis. This herein mini-review provides the experimental and observational evidence that a specific phenothiazine, thioridazine, will contribute to cure any form of drug-resistant tuberculosis. This antipsychotic agent is no longer under patent protection for its initial use. The reader is informed on the recent developments in patenting this compound for "new use" with a special emphasis on the aspects of drug-resistance. Given that economic motivation can stimulate the use of this drug as an antitubercular agent, future prospects are also discussed.

Original languageEnglish
Pages (from-to)206-212
Number of pages7
JournalRecent Patents on Anti-Infective Drug Discovery
Volume8
Issue number3
DOIs
Publication statusPublished - 2013

Fingerprint

Thioridazine
Multidrug-Resistant Tuberculosis
Patents
Pulmonary Tuberculosis
Antitubercular Agents
Terminally Ill
Drug Resistance
Pharmaceutical Preparations
Antipsychotic Agents
Economics
phenothiazine

Keywords

  • Curing of XDR TB
  • Mechanism of killing
  • Mycobacterium tuberculosis
  • Thioridazine

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Drug Discovery
  • Medicine(all)

Cite this

@article{d421cb09716a4deaaddc56454d072626,
title = "The mechanism by which the phenothiazine thioridazine contributes to cure problematic drug-resistant forms of pulmonary tuberculosis: Recent patents for {"}new use{"}",
abstract = "At this moment, over half million patients suffer from multi-drug resistant tuberculosis (MDR-TB) according to the data from the WHO. A large majority is terminally ill with essentially incurable pulmonary tuberculosis. This herein mini-review provides the experimental and observational evidence that a specific phenothiazine, thioridazine, will contribute to cure any form of drug-resistant tuberculosis. This antipsychotic agent is no longer under patent protection for its initial use. The reader is informed on the recent developments in patenting this compound for {"}new use{"} with a special emphasis on the aspects of drug-resistance. Given that economic motivation can stimulate the use of this drug as an antitubercular agent, future prospects are also discussed.",
keywords = "Curing of XDR TB, Mechanism of killing, Mycobacterium tuberculosis, Thioridazine",
author = "Leonard Amaral and Ana Martins and G. Spengler and Attila Hunyadi and J. Moln{\'a}r",
year = "2013",
doi = "10.2174/1574891X08666131210141521",
language = "English",
volume = "8",
pages = "206--212",
journal = "Recent Patents on Anti-Infective Drug Discovery",
issn = "1574-891X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - The mechanism by which the phenothiazine thioridazine contributes to cure problematic drug-resistant forms of pulmonary tuberculosis

T2 - Recent patents for "new use"

AU - Amaral, Leonard

AU - Martins, Ana

AU - Spengler, G.

AU - Hunyadi, Attila

AU - Molnár, J.

PY - 2013

Y1 - 2013

N2 - At this moment, over half million patients suffer from multi-drug resistant tuberculosis (MDR-TB) according to the data from the WHO. A large majority is terminally ill with essentially incurable pulmonary tuberculosis. This herein mini-review provides the experimental and observational evidence that a specific phenothiazine, thioridazine, will contribute to cure any form of drug-resistant tuberculosis. This antipsychotic agent is no longer under patent protection for its initial use. The reader is informed on the recent developments in patenting this compound for "new use" with a special emphasis on the aspects of drug-resistance. Given that economic motivation can stimulate the use of this drug as an antitubercular agent, future prospects are also discussed.

AB - At this moment, over half million patients suffer from multi-drug resistant tuberculosis (MDR-TB) according to the data from the WHO. A large majority is terminally ill with essentially incurable pulmonary tuberculosis. This herein mini-review provides the experimental and observational evidence that a specific phenothiazine, thioridazine, will contribute to cure any form of drug-resistant tuberculosis. This antipsychotic agent is no longer under patent protection for its initial use. The reader is informed on the recent developments in patenting this compound for "new use" with a special emphasis on the aspects of drug-resistance. Given that economic motivation can stimulate the use of this drug as an antitubercular agent, future prospects are also discussed.

KW - Curing of XDR TB

KW - Mechanism of killing

KW - Mycobacterium tuberculosis

KW - Thioridazine

UR - http://www.scopus.com/inward/record.url?scp=84901773492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901773492&partnerID=8YFLogxK

U2 - 10.2174/1574891X08666131210141521

DO - 10.2174/1574891X08666131210141521

M3 - Article

C2 - 24320229

AN - SCOPUS:84901773492

VL - 8

SP - 206

EP - 212

JO - Recent Patents on Anti-Infective Drug Discovery

JF - Recent Patents on Anti-Infective Drug Discovery

SN - 1574-891X

IS - 3

ER -